Document is current
Any future updates will be listed below
-
Authors
Baldus, Stephan
Beyer-Westendorf, Jan
Möllmann, Helge
Rottbauer, Wolfgang
Beyerlein, Elisabeth
Goette, Andreas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04519944 at ClinicalTrials.govDocuments that mention this clinical trial
Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
https://doi.org/10.1038/s41598-023-44345-7
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 30 May 2023
Accepted: 6 October 2023
First Online: 25 October 2023
Competing interests
: SB has received direct personal payments including speaker, honoraria, consultancy, advisory board, investigator and committee member fees from Bayer Vital, Daiichi Sankyo, Edwards Lifescience, and MSD Sharp and Dohme GmbH. Independent of the above activities, he has also received travel and meeting support from Amgen Inc., Bayer Vital, Daiichi Sankyo, and Novartis, and research funding (under his direct/personal responsibility) from Pfizer. JBW has received honoraria and research support from Bayer AG, Boehringer Ingelheim, Daiichi Sankyo, Doasense, Pfizer and Portola/Alexion. He has also received honoraria for Steering Committee activities for the ENCOURAGE-AF study. HM reports having received honoraria for Advisory Board activities and research support from Daiichi Sankyo. WR reports having received honoraria for Advisory Board activities and research support from Daiichi Sankyo. EB is employee of Daiichi Sankyo Europe GmbH. AG has received an EU Grant Horizon 2020 MAESTRIA Consortium; grant number 965286. Speaker fees from Abbott, Astra Zeneca, Bayer Health Care, Berlin Chemie, Biotronik, Boehringer Ingelheim, BMS/Pfizer, Boston Scientific, Daiichi-Sankyo, Medtronic, Omeicos, Sanofi-Aventis and Roche.
